SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027

AB Science SA EURONEXT:AB

AB